Word

MEDINCELL

Status

Registered

Status Code

700

Status Date

Tuesday, June 16, 2020

Serial Number

88404466

Registration Number

6077768

Registration Date

Tuesday, June 16, 2020

Mark Type

3000

Filing Date

Friday, April 26, 2019

Published for Opposition

Tuesday, March 31, 2020

Trademark Owner History

MedinCell S.A. - Original Registrant

Classifications

5 Pharmaceutical preparations and substances for use in contraception, for the treatment of infectious, genetic, metabolic, endocrine, cardiovascular, oncological, inflammatory, respiratory, neurological, hormonal and cognitive diseases and disorders, and for the treatment of substance abuse related diseases and disorders; pharmaceutical preparations, namely, a drug delivery system comprising pharmaceutical compositions for subcutaneous or intraarticular administration for the continuous release of therapeutic agents for use in contraception, for the treatment of infectious, genetic, metabolic, endocrine, cardiovascular, oncological, inflammatory, respiratory, neurological, hormonal and cognitive diseases and disorders, and for the treatment of substance abuse related diseases and disorders; veterinary preparations and substances for use in contraception, for the treatment of infectious, genetic, metabolic, endocrine, cardiovascular, oncological, inflammatory, respiratory, neurological, hormonal and cognitive diseases and disorders, and for the treatment of substance abuse related diseases and disorders; veterinary preparations, namely, a drug delivery system comprising compositions that facilitate continuous release delivery of a wide variety of therapeutic subcutaneous or intraarticular veterinary agents; pharmaceutical compositions for use in contraception, for the treatment of infectious, genetic, metabolic, endocrine, cardiovascular, oncological, inflammatory, respiratory, neurological, hormonal and cognitive diseases and disorders, and for the treatment of substance abuse related diseases and disorders; Drug delivery agents consisting of compounds that facilitate delivery of a wide range of pharmaceutical and veterinary pharmaceutical preparations; Drug delivery agents in the form of compounds that facilitate controlled release delivery of subcutaneous or intraarticular active ingredients for a wide variety of pharmaceuticals and veterinary pharmaceutical preparations; Drug delivery agents in the form of drug delivery compounds that facilitate sustained or extended release of the active ingredients for a wide variety of pharmaceuticals and veterinary pharmaceutical preparations; Drug delivery agents in the form of compounds that facilitate delivery of injectable pharmaceutical and veterinary pharmaceutical preparations; sustained or extended release drug delivery agents being compounds used to facilitate delivery of drugs, sold as an integral component of pharmaceutical and veterinary pharmaceutical preparations for use in contraception, for the treatment of infectious, genetic, metabolic, endocrine, cardiovascular, oncological, inflammatory, respiratory, neurological, hormonal and cognitive diseases and disorders, and for the treatment of substance abuse related diseases and disorders; chemical preparations for medical or pharmaceutical use for use in contraception, for the treatment of infectious, genetic, metabolic, endocrine, cardiovascular, oncological, inflammatory, respiratory, neurological, hormonal and cognitive diseases and disorders, and for the treatment of substance abuse related diseases and disorders; Carriers and mediums being drug delivery agents comprised of compounds for facilitating the delivery of pharmaceutical and veterinary pharmaceutical preparations for use in contraception, for the treatment of infectious, genetic, metabolic, endocrine, cardiovascular, oncological, inflammatory, respiratory, neurological, hormonal and cognitive diseases and disorders, and for the treatment of substance abuse related diseases and disorders; pharmaceutical and veterinary pharmaceutical preparations and substances for subcutaneous delivery for use in contraception, for the treatment of infectious, genetic, metabolic, endocrine, cardiovascular, oncological, inflammatory, respiratory, neurological, hormonal and cognitive diseases and disorders, and for the treatment of substance abuse related diseases and disorders

The color(s) black and blue is/are claimed as a feature of the mark.
The mark consists of the word "MedinCell" in black letters with a blue design consisting of two horizontally oriented conjoined semi-circles located above the word "Cell" with a single vertically oriented semi-circle conjoined to the right of the two horizontally oriented conjoined semi-circles.

Trademark Events

Jun 16, 2020

Registered-Principal Register

Mar 31, 2020

Official Gazette Publication Confirmation E-Mailed

Mar 31, 2020

Published For Opposition

Mar 11, 2020

Notification Of Notice Of Publication E-Mailed

Feb 27, 2020

Electronic Record Review Complete

Feb 7, 2020

On Hold - Electronic Record Review Required

Jan 31, 2020

Approved For Pub - Principal Register

Jan 31, 2020

Examiner's Amendment Entered

Jan 31, 2020

Notification Of Examiners Amendment E-Mailed

Jan 31, 2020

Examiners Amendment E-Mailed

Jan 31, 2020

Examiners Amendment -Written

Jan 9, 2020

Teas/Email Correspondence Entered

Jan 8, 2020

Correspondence Received In Law Office

Jan 8, 2020

Teas Response To Office Action Received

Jul 10, 2019

Notification Of Non-Final Action E-Mailed

Jul 10, 2019

Non-Final Action E-Mailed

Jul 10, 2019

Non-Final Action Written

Jul 9, 2019

Assigned To Examiner

May 15, 2019

Notice Of Design Search Code E-Mailed

May 14, 2019

New Application Office Supplied Data Entered In Tram

Apr 30, 2019

New Application Entered In Tram